Cymabay Therapeutics
CBAY
CBAY was delisted on the 21st of March, 2024.
130 hedge funds and large institutions have $251M invested in Cymabay Therapeutics in 2021 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 46 increasing their positions, 34 reducing their positions, and 32 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
35% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 34
10% less funds holding
Funds holding: 145 → 130 (-15)
22% less capital invested
Capital invested by funds: $322M → $251M (-$70.3M)
44% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 32
62% less call options, than puts
Call options by funds: $1.32M | Put options by funds: $3.45M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
+$8.06M |
| 2 |
Millennium Management
New York
|
+$3.81M |
| 3 |
BlackRock
New York
|
+$3.08M |
| 4 |
Renaissance Technologies
New York
|
+$2.59M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$2.53M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$5.07M |
| 2 |
Goldman Sachs
New York
|
-$4.57M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$3.89M |
| 4 |
VC
Vivo Capital
Palo Alto,
California
|
-$3.36M |
| 5 |
State Street
Boston,
Massachusetts
|
-$2.79M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
151
Rafferty Asset Management
New York
| – | -$98K | -17,061 | Closed |
|
|
PAMU
152
Pictet Asset Management (UK)
London,
United Kingdom
| – | -$76K | -13,200 | Closed |
|
153
Creative Planning
Overland Park,
Kansas
| – | -$71K | -12,449 | Closed |
|
154
Ohio Public Employees Retirement System (OPERS)
Columbus,
Ohio
| – | -$69K | -11,958 | Closed |
|
|
AIM
155
Aigen Investment Management
New York
| – | -$62K | -10,785 | Closed |
|
|
PHK
156
Point72 Hong Kong
Hong Kong
| – | -$57K | -9,868 | Closed |
|
|
EAM
157
Eagle Asset Management
St Petersburg,
Florida
| – | -$21K | -3,867 | Closed |
|
158
US Bancorp
Minneapolis,
Minnesota
| – | -$8K | -1,333 | Closed |
|
|
EW
159
Evoke Wealth
Los Angeles,
California
| – | -$2K | -333 | Closed |
|
|
HFS
160
Hantz Financial Services
Southfield,
Michigan
| – | +$404 | +75 | New |
|
CBAY Hedge Fund Activity: Q1 2021 in Review
130 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q1 2021, worth a combined $251M — down 22% from $322M a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of CBAY and 18 opened new positions — a net loss of 14 holders — while 34 trimmed existing stakes and 46 added.
The largest buyer was Commodore Capital, adding an estimated $8.06M. The largest seller was Citadel Advisors, cutting an estimated $5.07M.
- 130 institutional investors held Cymabay Therapeutics (CBAY) as of Q1 2021, down from 145 in Q4 2020.
- Funds reported $251M of Cymabay Therapeutics stock for Q1 2021, down 22% quarter-over-quarter.
- 18 funds opened new Cymabay Therapeutics positions in Q1 2021 and 32 closed out, a net change of -14 holders.
- The largest Cymabay Therapeutics buyer in Q1 2021 was Commodore Capital, an estimated $8.06M added.
- The largest Cymabay Therapeutics seller in Q1 2021 was Citadel Advisors, an estimated $5.07M sold.
Based on aggregated 13F filings for Q1 2021.